Stock 4528 ONO PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Ono Pharmaceutical Co., Ltd.

Equities

4528

JP3197600004

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-25 am EDT 		5-day change 1st Jan Change
2,270 JPY -1.09% Intraday chart for Ono Pharmaceutical Co., Ltd. -2.45% -9.80%
Mar. 21 ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL CI
Mar. 14 Sibylla Biotech Enters Strategic Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. in Central Nervous System Disorders CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ono Pharmaceutical : Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area
PU
Ono Pharmaceutical : Announcement on Changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers
PU
Ono Pharmaceutical : Announces Completion of Cancellation of Treasury Stock
PU
Ono Announces General Sponsorship for the 'Theme Weeks' as Bronze Partner, at the Expo 2025 Osaka, Kansai, Japan
AQ
Final dividend
FA
Ono Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford
AQ
Equillium to Present at the H.C. Wainwright Autoimmune and Inflammatory Disease Conference and the LD Micro Invitational Conference
AQ
Ono Pharmaceutical : Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford
PU
ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL
CI
Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders
AQ
Ono Pharmaceutical : Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders
PU
Sibylla Biotech Enters Strategic Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. in Central Nervous System Disorders
CI
Ono Pharmaceutical : U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PU
Ono Pharmaceutical Co., Ltd. Enters into A University-Wide, Research Alliance Agreement with Harvard University
CI
Jefferies Adjusts Ono Pharmaceutical’s Price Target to 2,400 Yen From 2,300 Yen, Keeps at Hold
MT
Ono Pharmaceutical : Enters into a License Agreement with NEX-I to Develop and Commercialize NXI-101
PU
Ono Pharmaceutical Announces Status of Acquisition of Own Shares
AQ
Ono Pharmaceutical : Announces Status and Completion of Acquisition of Own Shares
PU
Tranche Update on Ono Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 25, 2023.
CI
Ono Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 25, 2023, has closed with 18,732,400 shares, representing 3.88% for ¥49,999.75 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4528 Stock
  4. News Ono Pharmaceutical Co., Ltd.